MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3233/jnd-210665

Медицинская библиотека · Journal of neuromuscular diseases · 2022

A Combined Prospective and Retrospective Comparison of Long-Term Functional Outcomes Suggests Delayed Loss of Ambulation and Pulmonary Decline with Long-Term Eteplirsen Treatment.

Mitelman Olga, Abdel-Hamid Hoda Z, Byrne Barry J, Connolly Anne M, Heydemann Peter, Proud Crystal, Shieh Perry B, Wagner Kathryn R, Dugar Ashish, Santra Sourav, Signorovitch James, Goemans Nathalie, investigators from the LNMRC Natural History study, McDonald Craig M, investigators from the CINRG Duchenne National History Study, Mercuri Eugenio, investigators from The DMD Italian Group, Mendell Jerry R

Сравнительное исследованиеСтатьяРандомизированное исследованиеПеревод в очереди

Аннотация

BACKGROUND

Studies 4658-201/202 (201/202) evaluated treatment effects of eteplirsen over 4 years in patients with Duchenne muscular dystrophy and confirmed exon-51 amenable genetic mutations. Chart review Study 4658-405 (405) further followed these patients while receiving eteplirsen during usual clinical care.

OBJECTIVE

To compare long-term clinical outcomes of eteplirsen-treated patients from Studies 201/202/405 with those of external controls.

METHODS

Median total follow-up time was approximately 6 years of eteplirsen treatment. Outcomes included loss of ambulation (LOA) and percent-predicted forced vital capacity (FVC%p). Time to LOA was compared between eteplirsen-treated patients and standard of care (SOC) external controls and was measured from eteplirsen initiation in 201/202 or, in the SOC group, from the first study visit. Comparisons were conducted using univariate Kaplan-Meier analyses and log-rank tests, and multivariate Cox proportional hazards models with regression adjustment for baseline characteristics. Annual change in FVC%p was compared between eteplirsen-treated patients and natural history study patients using linear mixed models with repeated measures.

RESULTS

Data were included from all 12 patients in Studies 201/202 and the 10 patients with available data from 405. Median age at LOA was 15.16 years. Eteplirsen-treated patients experienced a statistically significant longer median time to LOA by 2.09 years (5.09 vs. 3.00 years, p < 0.01) and significantly attenuated rates of pulmonary decline vs. natural history patients (FVC%p change: -3.3 vs. -6.0 percentage points annually, p < 0.0001).

CONCLUSIONS

Study 405 highlights the functional benefits of eteplirsen on ambulatory and pulmonary function outcomes up to 7 years of follow-up in comparison to external controls.

Для цитирования: Mitelman Olga, Abdel-Hamid Hoda Z, Byrne Barry J, Connolly Anne M, Heydemann Peter, Proud Crystal, Shieh Perry B, Wagner Kathryn R, Dugar Ashish, Santra Sourav, Signorovitch James, Goemans Nathalie, investigators from the LNMRC Natural History study, McDonald Craig M, investigators from the CINRG Duchenne National History Study, Mercuri Eugenio, investigators from The DMD Italian Group, Mendell Jerry R. A Combined Prospective and Retrospective Comparison of Long-Term Functional Outcomes Suggests Delayed Loss of Ambulation and Pulmonary Decline with Long-Term Eteplirsen Treatment.. Journal of neuromuscular diseases. 2022. DOI: 10.3233/jnd-210665.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.